Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vigilant Hikma bounces from Arab Spring with $200m on hand for acquisitions

This article was originally published in Scrip

Executive Summary

Following the political and social upheaval of the Arab Spring, Hikma Pharmaceuticals is poised for expansion into markets that are now much more receptive than before. Said Darwazah, CEO of the Jordan-based speciality pharma group, told Scrip that while the political disruptions in the Middle East only cut a company-estimated $20 million from sales revenue in 2011, the situation has transformed some markets into an opportunity for accelerated growth.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC016622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel